Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
← catalyst calendarNCT06138743 · readout in 134 d
Sponsored by Sarepta Therapeutics, Inc. (industry) · SRPT — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
78estimated
Sites
35
Countries
Australia, Belgium, Canada +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-04 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myotonic Dystrophy 1
Interventions
- Drug: SRP-1003 IV Infusion — also filed as ARO-DM1 IV Infusion
- Drug: Placebo IV Infusion
- Drug: SRP-1003 SC Injection — also filed as ARO-DM1 SC Injection
- Drug: Placebo SC Injection
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment-emergent Adverse Events Over Time Through End of Study (EOS)
measured Single-dose phase (Part 1): Up to Day 90 (EOS); multiple-dose phase (Part 2): Up to Day 180 (EOS)
Permalink · SRPT's whole pipeline · Catalyst calendar · Every registered study · What changed